样式: 排序: IF: - GO 导出 标记为已读
-
Impact of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-03-17 Keito Suzuki, Yutaka Yasui, Kaoru Tsuchiya, Hiroaki Matsumoto, Yudai Yamazaki, Naoki Uchihara, Yuki Tanaka, Haruka Miyamoto, Michiko Yamada-Shimizu, Taisei Keitoku, Risa Okada, Mayu Higuchi, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Nobuharu Tamaki, Hiroyuki Nakanishi, Yuka Takahashi, Yasuhiro Asahina, Ryuichi Okamoto, Masayuki Kurosaki, Namiki Izumi
-
Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-03-14 Tyng‐Yuan Jang, Po‐Cheng Liang, Dae Won Jun, Jang Han Jung, Hidenori Toyoda, Chih‐Wen Wang, Man‐Fung Yuen, Ka Shing Cheung, Satoshi Yasuda, Sung Eun Kim, Eileen L Yoon, Jihyun An, Masaru Enomoto, Ritsuzo Kozuka, Makoto Chuma, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Masanori Atsukawa, Taeang Arai, Korenobu Hayama, Masatoshi Ishigami, Yong Kyun Cho, Eiichi Ogawa, Hyoung Su Kim, Jae‐Jun Shim
Background and AimThe benefits of entecavir (ETV) versus tenofovir disoproxil fumarate (TDF) in reducing the development of chronic hepatitis B (CHB)‐related hepatocellular carcinoma remain controversial. Whether mortality rates differ between patients with CHB treated with ETV and those treated with TDF is unclear.MethodsA total of 2542 patients with CHB treated with either ETV or TDF were recruited
-
Fecal microbiota transplantation as an early therapeutic option in treatment refractory Clostridioides difficile infection J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-03-08 OC Buldukoglu, S Ocal, AH Cekin
-
Impact of the COVID‐19 pandemic on gastric surgery in Japan: A nationwide study using interrupted time‐series analyses J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-03-08 Misuzu Fujita, Kazuya Yamaguchi, Kengo Nagashima, Kiminori Suzuki, Tokuzo Kasai, Hideyuki Hashimoto, Yoshihiro Onouchi, Daisuke Sato, Takehiko Fujisawa, Akira Hata
-
Clinical course of small gastric subepithelial lesion less than 20 mm diagnosed by endoscopic ultrasound‐guided fine‐needle aspiration J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-03-07 Ryosuke Kobayashi, Kingo Hirasawa, Yuichiro Ozeki, Atsushi Sawada, Masafumi Nishio, Chiko Sato, Haruo Miwa, Takashi Kaneko, Kazuya Sugimori, Shin Maeda
-
Issue Information J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-03-04
No abstract is available for this article.
-
Comparing a fecal immunochemical test and circulating tumor DNA blood test for colorectal cancer screening adherence J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-03-02 Geraldine Laven‐Law, Erin L Symonds, Jean M Winter, Gang Chen, Ingrid H Flight, Donna Hughes‐Barton, Carlene J Wilson, Graeme P Young
-
Performance of the Asia–Pacific Colorectal Screening score in stratifying the risk of advanced colorectal neoplasia: A meta‐analysis and systematic review J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-03-01 Mai Ngoc Luu, Nhi Ai Trinh, Truc Le Thanh Tran, Thinh Phuong Dang, Toru Hiyama, Duc Trong Quach
-
Association of metabolic dysfunction‐associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-29 Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Motoko Sei, Hiroyuki Ueda, Reiko Yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Fumika Nakamura, Tetsu Tomonari, Koichi Okamoto, Yutaka Kawano, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono, Tetsuji Takayama
Background and AimAlthough erosive esophagitis (EE) is associated with fatty liver and metabolic dysregulation, the association between EE and metabolic dysfunction‐associated steatotic liver disease (MASLD) remains unclear. Thus, this study aimed to investigate the longitudinal association between MASLD and EE.MethodsWe included 1578 patients without EE at baseline who underwent more than two health
-
Safety of biliary drainage with 6‐mm metallic stent for preoperative obstructive jaundice in pancreatic cancer: PURPLE SIX STUDY J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-29 Shota Harai, Susumu Hijioka, Reiko Yamada, Takeshi Ogura, Mitsuharu Fukasawa, Atsushi Okuda, Hideyuki Horike, Dai Inoue, Masanari Sekine, Yusuke Ishida, Takehiko Koga, Hidetoshi Kitamura, Yasuhito Tanaka, Motohiro Yoshinari, Katsumasa Kobayashi, Mark Chatto, Daiki Yamashige, Yuki Kawasaki, Yoshikuni Nagashio, Takuji Okusaka
-
PARVB and HSD17B13 variants are associated with nonalcoholic fatty liver disease in children J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-29 Kyung Jae Lee, Jin Soo Moon, Jin Gyu Lim, Homin Huh, Jeong Eun Ahn, Lia Kim, Nan Young Kim, Jae Sung Ko
-
Constipated patients with functional defecatory disorder have secondary rectal hyposensitivity due to altered rectal biomechanics J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-29 Matthew Woo, Armaan Pandey, Dorothy Li, Michelle Buresi, Yasmin Nasser, Christopher N Andrews
-
Big data approach in the field of gastric and colorectal cancer research J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-27 Ka Shing Cheung
Big data is characterized by three attributes: volume, variety,, and velocity. In healthcare setting, big data refers to vast dataset that is electronically stored and managed in an automated manner and has the potential to enhance human health and healthcare system. In this review, gastric cancer (GC) and postcolonoscopy colorectal cancer (PCCRC) will be used to illustrate application of big data
-
Challenges for hepatitis B control in Asia-Pacific areas: Consolidating vaccination and rolling-out antiviral therapies J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-27 Pei-Jer Chen
Chronic hepatitis B (CHB) was, and still is, a prevalent liver disease in the world, especially high in the Asia-Pacific areas. With the advent of preventive vaccines and effective viral suppression drugs and active implementations, CHB has gradually become under control. The world-wide prevalence reduces from 4.2% in 1980 to 3.2% in 2020 study. CHB patients receiving long-term antiviral therapies
-
Gastrointestinal: Langerhans cell histiocytosis in an adult with anal protrusion and multiple colorectal ulcers J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-28 QT Truong, NHH Pham, TH Doan, VT Hoang, DT Hoang, CT Trinh, NT Tran
A 56-year-old woman with no significant past medical history presented with small pimple-like lesions around her perianal area for more than 3 months. The condition gradually worsened, and the patient experienced pain during defecation and reported a 3-kg weight loss. She admitted rare alcohol consumption, no smoking, and a noncontributing family history. Examination revealed that the anal lesions
-
The effect of incorporating domain knowledge with deep learning in identifying benign and malignant gastric whitish lesions: A retrospective study J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-28 Xiaoquan Zeng, Lang Yang, Zehua Dong, Dexin Gong, Yanxia Li, Yunchao Deng, Hongliu Du, Xun Li, Youming Xu, Chaijie Luo, Junxiao Wang, Xiao Tao, Chenxia Zhang, Yijie Zhu, Ruiqing Jiang, Liwen Yao, Lianlian Wu, Peng Jin, Honggang Yu
-
Revolution of Helicobacter pylori treatment J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-28 Yoshio Yamaoka
Helicobacter pylori infection is a major global health concern, and its management has witnessed a revolutionary shift with the emergence of antibiotic resistance. In this review, I explore the mechanisms of H. pylori antibiotic resistance and highlight the critical need for susceptibility‐based eradication treatments. The increasing prevalence of antibiotic‐resistant strains requires innovative approaches
-
Surveillance esophagogastroduodenoscopy using linked color imaging and narrow-band imaging: A multicenter randomized controlled trial J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-25 Marina Kubo, Shoko Ono, Osamu Dohi, Hayato Fukui, Takuto Hikichi, Tsunetaka Kato, Momoko Tsuda, Mio Matsumoto, Sosuke Kato, Rieko Mukai, Nobuaki Yagi, Ryo Takagi, Naoya Sakamoto, Mototsugu Kato
-
mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-25 Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Kazuya Kariyama, Satoshi Yasuda, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Tomomitsu Matono, Shinichiro Nakamura, Hidenori Toyoda
The study aims to develop a novel predictive model including the fibrosis (FIB)-3 index for hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C virus (HCV) who achieved sustained virological response (SVR) with direct-acting antiviral (DAA) therapy.
-
Gastrointestinal: Cytomegalovirus enteritis with severe hypoalbuminemia in an immunocompetent patient J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-26 K Miyaguchi, M Hamada, Y Tsuzuki, H Imaeda
A 70-year-old man, previously treated for hypertension and diabetes mellitus, presented with a 3-month history of diarrhea and sought care at an outpatient clinic. Blood tests revealed severe hypoalbuminemia (albumin: 1.3 mg/dL). Although urinalysis and renal function test findings were normal, the C-reactive protein and white blood cell levels were mildly elevated (white blood cells: 10, 080 cells/μL;
-
Endoscopy for Crohn's disease‐related strictures: Can we finally replace the surgeons? J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-24 Nik Arsyad Nik Affendi, Ida Hilmi
Despite the advancements in medical therapy, Crohn's disease (CD) remains an unpredictable disease with a significant proportion of patients developing complications such as stricture, fistula, or even perforation requiring surgical intervention. In particular, stricturing CD remains a significant problem with approximately 50% of CD patients developing a stricture in their lifetime.1 The pathogenesis
-
Feasibility of new-generation endocytoscopy for the real-time diagnosis of ampullary lesions: A pilot study (with video) J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-22 Ming-Lun Han, Wen-Lun Wang, Ching-Tai Lee, Min-Shu Hsieh, Ming-Chang Tsai, Yi-Chung Chan, Yu-Long Chu, Hsiu-Po Wang
-
Predicting the risk of pancreatic cancer in women with new-onset diabetes mellitus J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-19 Sitwat Ali, Michael Coory, Peter Donovan, Renhua Na, Nirmala Pandeya, Sallie-Anne Pearson, Katrina Spilsbury, Karen Tuesley, Susan J. Jordan, Rachel E. Neale
People with new-onset diabetes mellitus (diabetes) could be a possible target population for pancreatic cancer surveillance. However, distinguishing diabetes caused by pancreatic cancer from type 2 diabetes remains challenging. We aimed to develop and validate a model to predict pancreatic cancer among women with new-onset diabetes.
-
Impact of metabolic unhealthiness and its changes on the risk of erosive esophagitis: a cohort study J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-21 Nam Hee Kim, Yoosoo Chang, Seungho Ryu, Chong Il Sohn
Background and AimWe aimed to compare the risk of erosive esophagitis (EE) among individuals with different phenotypes based on metabolic health status and obesity and investigate the role of changes in metabolic health in EE risk.MethodsA cohort of 258 892 asymptomatic adults without EE at baseline who underwent ollow‐up esophagogastroduodenoscopy (EGD) were categorized into the following four groups
-
JGH has a new leader J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-21 Joseph Sung
The Journal of Gastroenterology and Hepatology is an international journal with special interest on the science and practice of gastroenterology, hepatology, and endoscopy that translates into better care of patients. It represents the community of gastroenterologists, hepatologists, GI surgeons, and scientists in the Asia Pacific Region. Over the years, its scientific standing is established by the
-
Therapeutic drug monitoring of vedolizumab therapy in inflammatory bowel disease J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-21 Casper Steenholdt, Ruben Due Lorentsen, Pernille Nørgaard Petersen, Ella SK Widigson, Charlotte Kloft, Rolf Anton Klaasen, Jørn Brynskov
-
TET1 inhibits liver fibrosis by blocking hepatic stellate cell activation J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-19 Jingjie Wang, Yitong Zhang, Yanyun Ma, Suhan Zhao, Jiucun Wang, Hongtan Chen, Jun Zhang, Jie Liu
-
Metabolic‐associated fatty liver disease and hepatocellular carcinoma: a prospective study of characteristics and response to therapy J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-19 NM Batt, B Rodrigues, S Bloom, R Sawhney, ES George, A Hodge, N Vootukuru, C McCrae, Surbhi Sood, SK Roberts, A Dev, S Bell, A Thompson, MC Ryan, W Kemp, PJ Gow, Siddharth Sood, AJ Nicoll
Background and AimThe rising incidence of hepatocellular carcinoma (HCC) in Australia is related to increasing rates of metabolic‐associated fatty liver disease (MAFLD). This study aimed to prospectively characterize the metabolic profile, lifestyle, biometric features, and response to treatment of HCC patients in an Australian population.MethodMulticenter prospective cohort analysis of newly diagnosed
-
Hepatitis C virus infection in patients undergoing surgery in a single tertiary academic center J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-15 Jae Seung Lee, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
Lack of awareness disturbs proper care for hepatitis C virus (HCV) infections in patients undergoing surgery. We investigated the status of HCV screening, confirmation, and treatment in patients who underwent surgery.
-
Metabolic fatty liver syndromes: where do we stand in 2024? J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-15 Wah-Kheong Chan, Jacob George
In 2020, the term metabolic dysfunction-associated fatty liver disease (MAFLD) was proposed, attributing the common disease we see in clinical practice, to its underlying pathophysiology (instead of telling us what it is not), and providing a set of positive diagnostic criteria (instead of being a diagnosis of exclusion).1, 2 The new term and its definition was soon endorsed by the Asian Pacific Association
-
Gastrointestinal: Carcinoma of the duodenal bulb with rapid growth and distant metastasis J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-15 Y Aoyama, Y Kono, Y Kawahara
A male patient in his 40s had undergone esophagogastroduodenoscopy (EGD) for cancer screening 2 years previously. A small bulge with a glandular orifice that had been suspected to be Brunner's gland hyperplasia was observed on the anterior surface of the duodenal bulb (Fig.1a). One year later, the glandular orifice had become reddish without changes in morphology or size (Fig.1b). Another year later
-
Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta-analysis of randomized controlled trials J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-14 Daniel Martin Simadibrata, Elvira Lesmana, Ronnie Fass
-
Comparison of postoperative survival between early-onset and late-onset adenocarcinoma of esophagogastric junction: a population-based study J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-14 Liubo Chen, Tian Jin, Yimin Fang, Gaoqi Wu, Ying Yuan
The prognosis of early-onset adenocarcinoma of esophagogastric junction (AEG) remains unclear. This research aimed at comparing the prognosis between early-onset and late-onset AEGs.
-
Issue Information J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-14
No abstract is available for this article.
-
Cost-effectiveness analysis of single colonoscopy versus single fecal test for colorectal cancer diagnosis and treatment J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-13 Fumiaki Ishibashi, Sho Suzuki, Konomi Kobayashi, Ryu Tanaka, Tomohiro Kawakami, Kentaro Mochida, Mizuki Nagai, Yuichi Ishibashi, Tetsuo Morishita
-
Cilostazol improves the prognosis after hepatectomy in rats with sinusoidal obstruction syndrome J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-13 Hiroaki Sugita, Shinichi Nakanuma, Seiichi Munesue, Tatsuya Ishikawa, Tomokazu Tokoro, Ryohei Takei, Mitsuyoshi Okazaki, Kaichiro Kato, Satoshi Takada, Isamu Makino, Noriyuki Ozaki, Yasuhiko Yamamoto, Shintaro Yagi
-
Postoperative adjuvant chemotherapy is important for improving long-term survival in patients with colorectal cancer liver metastases undergoing simultaneous resection J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-07 Wenhui Zhong, Bowen Xu, Yiming Lu, Jianping Chang, Lin Xu, Hong Zhao, Xu Che
-
Individualized small bowel preparation for computed tomography enterography: A prospective randomized controlled trial J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-07 Yi-Ning Sun, Yue-Yue Li, Meng-Qi Zheng, Yong-Feng Liang, Rui Ji, Xiao-Xiao Yang, Jun-Yan Qu, Zhen Li, Xiu-Li Zuo, Yan-Qing Li
The study aims to evaluate the feasibility of body mass index (BMI)-based individualized small bowel preparation for computed tomography enterography (CTE).
-
Diagnostic algorithm for neonatal intrahepatic cholestasis integrating single-gene testing and next-generation sequencing in East Asia J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-07 Jong Woo Hahn, Heerah Lee, MinSoo Shin, Moon Woo Seong, Jin Soo Moon, Jae Sung Ko
-
Beyond a vestigial organ: effects of the appendix on gut microbiome and colorectal cancer J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-02-01 Daniel Ren Yi Yap, Rashid N Lui, Jens Samol, Joanne Ngeow, Joseph JY Sung, Sunny H Wong
The role of appendectomy in the pathogenesis of colorectal cancer (CRC) is a recent topic of contention. Given that appendectomy remains one of the most commonly performed operations and a first-line management strategy of acute appendicitis, it is inherently crucial to elucidate the association between prior appendectomy and subsequent development of CRC, as there may be long-term health repercussions
-
The impact of sodium-glucose cotransporter-2 inhibitors on outcome of patients with diabetes mellitus and colorectal cancer J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-01-31 Cho-Han Chiang, Cho-Hung Chiang, Yuan Ping Hsia, Aunchalee Jaroenlapnopparat, Chuan-Sheng Horng, Kit Yee Wong, Shih-Syuan Wang, Yu-Cheng Chang, Brian Shiian Chen, Yu-Ze Luan, Chun-Hao Wang, Tomas G. Neilan, Cho-Hsien Chiang, Cheng-Ming Peng, Her-Shyong Shiah
-
Issue Information J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-01-29
No abstract is available for this article.
-
Statin use in cirrhosis and its association with incidence of portal vein thrombosis J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-01-25 Waseem Amjad, Zhenghui Jiang, Michelle Lai
-
Histological differentiation between sporadic and colitis-associated intestinal cancer in a nationwide study: A propensity-score-matched analysis J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-01-25 Motoi Uchino, Hiroki Ikeuchi, Tatsuki Noguchi, Koji Okabayashi, Kitaro Futami, Shinji Tanaka, Hiroki Ohge, Kazuhiro Watanabe, Michio Itabashi, Kinya Okamoto, Yoshiki Okita, Tsunekazu Mizushima, Yusuke Mizuuchi, Kazutaka Yamada, Yoshifumi Shimada, Yu Sato, Hideaki Kimura, Kenichi Takahashi, Koya Hida, Yusuke Kinugasa, Junji Okuda, Koji Daito, Fumikazu Koyama, Hideki Ueno, Takayuki Yamamoto, Tsunekazu
-
Evaluating false-positive detection in a computer-aided detection system for colonoscopy J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-01-25 Taishi Okumura, Kenichiro Imai, Masashi Misawa, Shin-ei Kudo, Kinichi Hotta, Sayo Ito, Yoshihiro Kishida, Kazunori Takada, Noboru Kawata, Yuki Maeda, Masao Yoshida, Yoichi Yamamoto, Tatsunori Minamide, Hirotoshi Ishiwatari, Junya Sato, Hiroyuki Matsubayashi, Hiroyuki Ono
-
Endoscopic retrograde cholangiopancreatography-obtained bile culture in acute cholangitis: retrospective analysis of bile cultures and risk factors in a tertiary care center J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-01-24 Petros Stathopoulos, Paulina Lerner, Philipp Astheimer, Lutz P. Breitling, Malte Zumblick, Michael Pararas, Michael Lohoff, Thomas M. Gress, Ulrike W. Denzer
-
A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-01-23 Daniel Martin Simadibrata, Elvira Lesmana, Ronnie Fass
Up to 40% of gastroesophageal reflux disease (GERD) patients experience inadequate symptom relief with a proton pump inhibitor (PPI), termed PPI-resistant or refractory GERD. Vonoprazan, a potassium-competitive acid blocker, has better efficacy than PPI in suppressing gastric acid secretion. This meta-analysis summarizes the efficacy and safety of vonoprazan for treating PPI-resistant GERD (both erosive
-
Carbon footprint and cost reduction by endoscopic grading of gastric intestinal metaplasia using narrow-band imaging J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-01-22 Jun-Hyung Cho, So-Young Jin, Suyeon Park
-
The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter study J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-01-22 Qianjun Zhuang, Aijun Liao, Qingling He, Chengxia Liu, Changqing Zheng, Xing Li, Youli Liu, Bangmao Wang, Side Liu, Yan Zhang, Rong Lin, Huixin Chen, Min Deng, Yanping Tang, Chiyi He, Weijie Dai, Haitao Tang, Lei Gong, Liangping Li, Baohong Xu, Changqing Yang, Bingxi Zhou, Dongxing Su, Qinghong Guo, Bin Li, Yongjian Zhou, Xiaoyang Wang, Sujuan Fei, Huili Wu, Sichen Wei, Zhihong Peng, Jianning Wang
Fexuprazan is a novel potassium-competitive acid blocker (P-CAB). This study aimed to explore the noninferior efficacy and safety of fexuprazan to esomeprazole in treating erosive esophagitis (EE).
-
One-day versus three-day low-residue diet bowel preparation regimens before colonoscopy: a meta-analysis of randomized controlled trials J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-01-22 Fan Wang, Xinxin Huang, Zhijie Wang, Ziwei Yan, Shuling Wang, Peng Pan, Zhaoshen Li, Yu Bai
-
A systematic critical appraisal of clinical practice guidelines of antithrombotic agents in gastrointestinal endoscopy using the AGREE II tool J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-01-22 Denisse Camille Dayto, Wojciech Blonski, Tea Reljic, Farina Klocksieben, Jeffrey Gill, Rene D. Gomez-Esquivel, Brijesh Patel, Pushpak Taunk, Andrew Sephien, Camille Thelin, Ambuj Kumar
The quality of clinical practice guidelines (CPGs) for the management of antithrombotic agents in patients undergoing gastrointestinal (GI) endoscopy has not been systematically appraised. The goal of this study was to evaluate the methodological quality of CPGs for the management of antithrombotic agents in periendoscopic period published within last 6 years.
-
Forecasting the future prevalence of inflammatory bowel disease in Korea through 2048: an epidemiologic study employing autoregressive integrated moving average models J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-01-17 Ji Eun Kim, Shin Ju Oh, Chang Kyun Lee
-
Mendelian-randomization study revealed causal relationship between nonalcoholic fatty liver disease and osteoporosis/fractures J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-01-19 Xiong Pei, Wei Jiang, Lianchi Li, Qingmin Zeng, Chang-Hai Liu, Ming Wang, Enqiang Chen, Taoyou Zhou, Hong Tang, Dongbo Wu
-
Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-01-19 Lingfeng Diao, Chendong Wang, Ran You, Bin Leng, Zeyu Yu, Qingyu Xu, Yuan Cheng, Guowen Yin
-
Circulating leptin in patients with nonalcoholic fatty liver disease-related liver fibrosis: a systematic review and a meta-analysis J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-01-18 Evangelia S. Makri, Kleo Evripidou, Stergios A. Polyzos
-
Can we predict who will respond to a low-FODMAP diet in irritable bowel syndrome? J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-01-18 Kee Huat Chuah, Sanjiv Mahadeva
Irritable bowel syndrome (IBS) is one of the most common disorders of gut–brain interaction (DGBI), characterized by abdominal pain or discomfort, associated with an alteration in stool consistency. The pathophysiology of IBS is complex and thought to result from the interaction of multiple biopsychosocial factors. As a result, most pharmacological-based therapy alone appears to have a modest impact
-
Rifaximin treatment shapes a unique metagenome-metabolism network in patients with decompensated cirrhosis J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-01-17 Mei-Tong Nie, Pei-Qin Wang, Pei-Mei Shi, Xia-Lu Hong, Xin Zhang, Baoyu Xiang, Menghui Zhang, Wei-Fen Xie
-
Preventing variceal rebleeding in cirrhotic patients with portal vein thrombosis: A systematic review and meta-analysis J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-01-17 Junyuan Zhu, Yifu Xia, Xiao Liu, Chunqing Zhang
-
Metabolic syndrome, its components, and gastrointestinal cancer risk: a meta-analysis of 31 prospective cohorts and Mendelian randomization study J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-01-17 Zhi-Qing Zhan, Ying-Zhou Chen, Ze-Min Huang, Yu-Hua Luo, Jia-Jian Zeng, Ye Wang, Juan Tan, Ying-Xuan Chen, Jing-Yuan Fang
-
The current and future clinical applications of capsule endoscopy J. Gastroenterol. Hepatol. (IF 4.1) Pub Date : 2024-01-18 Agnes H Y Ho, Rashid N Lui
Capsule endoscopy (CE) has become an increasingly popular modality in facilitating the diagnosis of gastrointestinal tract pathologies that are beyond the reach of conventional endoscopy in the recent decades. Largely attributed to the lack of control of the capsule movement, most commercially available CEs are for diagnostic purposes at present. Yet, with the advancement in the capsule design and